Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

A. Peasland, L. Z. Wang, E. Rowling, S. Kyle, T. Chen, A. Hopkins, William Arthur Cliby, Jann N Sarkaria, G. Beale, R. J. Edmondson, N. J. Curtin

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Background: The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a key role in the signalling of stalled replication forks and DNA damage to cell cycle checkpoints and DNA repair. It has long been recognised as an important target for cancer therapy but inhibitors have proved elusive. As NU6027, originally developed as a CDK2 inhibitor, potentiated cisplatin in a CDK2-independent manner we postulated that it may inhibit ATR. Methods: Cellular ATR kinase activity was determined by CHK1 phosphorylation in human fibroblasts with inducible dominant-negative ATR-kinase dead expression and human breast cancer MCF7 cells. Cell cycle effects and chemo-and radiopotentiation by NU6027 were determined in MCF7 cells and the role of mismatch repair and p53 was determined in isogenically matched ovarian cancer A2780 cells.Results:NU6027 is a potent inhibitor of cellular ATR activity (IC50 6.7μM) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner. NU6027 attenuated G2/M arrest following DNA damage, inhibited RAD51 focus formation and increased the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy but not the antimitotic, paclitaxel. In A2780 cells sensitisation to cisplatin was greatest in cells with functional p53 and mismatch repair (MMR) and sensitisation to temozolomide was greatest in p53 mutant cells with functional MMR. Importantly, NU6027 was synthetically lethal when DNA single-strand break repair is impaired either through poly(ADP-ribose) polymerase (PARP) inhibition or defects in XRCC1. Conclusion: NU6027 inhibits ATR, impairing G2/M arrest and homologous recombination thus increasing sensitivity to DNA-damaging agents and PARP inhibitors. It provides proof of concept data for clinical development of ATR inhibitors.

Original languageEnglish (US)
Pages (from-to)372-381
Number of pages10
JournalBritish Journal of Cancer
Volume105
Issue number3
DOIs
StatePublished - Jul 26 2011

Fingerprint

Ovarian Neoplasms
Breast Neoplasms
Cell Line
DNA Mismatch Repair
Cisplatin
Phosphotransferases
temozolomide
MCF-7 Cells
DNA Damage
Antimitotic Agents
Single-Stranded DNA Breaks
Ataxia Telangiectasia
Hydroxyurea
Poly(ADP-ribose) Polymerases
Homologous Recombination
DNA
Paclitaxel
Cell Cycle Checkpoints
DNA Repair
Inhibitory Concentration 50

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Peasland, A., Wang, L. Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., ... Curtin, N. J. (2011). Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. British Journal of Cancer, 105(3), 372-381. https://doi.org/10.1038/bjc.2011.243

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. / Peasland, A.; Wang, L. Z.; Rowling, E.; Kyle, S.; Chen, T.; Hopkins, A.; Cliby, William Arthur; Sarkaria, Jann N; Beale, G.; Edmondson, R. J.; Curtin, N. J.

In: British Journal of Cancer, Vol. 105, No. 3, 26.07.2011, p. 372-381.

Research output: Contribution to journalArticle

Peasland, A, Wang, LZ, Rowling, E, Kyle, S, Chen, T, Hopkins, A, Cliby, WA, Sarkaria, JN, Beale, G, Edmondson, RJ & Curtin, NJ 2011, 'Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines', British Journal of Cancer, vol. 105, no. 3, pp. 372-381. https://doi.org/10.1038/bjc.2011.243
Peasland, A. ; Wang, L. Z. ; Rowling, E. ; Kyle, S. ; Chen, T. ; Hopkins, A. ; Cliby, William Arthur ; Sarkaria, Jann N ; Beale, G. ; Edmondson, R. J. ; Curtin, N. J. / Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. In: British Journal of Cancer. 2011 ; Vol. 105, No. 3. pp. 372-381.
@article{0d5de60f88a14a42821f77fd7402549d,
title = "Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines",
abstract = "Background: The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a key role in the signalling of stalled replication forks and DNA damage to cell cycle checkpoints and DNA repair. It has long been recognised as an important target for cancer therapy but inhibitors have proved elusive. As NU6027, originally developed as a CDK2 inhibitor, potentiated cisplatin in a CDK2-independent manner we postulated that it may inhibit ATR. Methods: Cellular ATR kinase activity was determined by CHK1 phosphorylation in human fibroblasts with inducible dominant-negative ATR-kinase dead expression and human breast cancer MCF7 cells. Cell cycle effects and chemo-and radiopotentiation by NU6027 were determined in MCF7 cells and the role of mismatch repair and p53 was determined in isogenically matched ovarian cancer A2780 cells.Results:NU6027 is a potent inhibitor of cellular ATR activity (IC50 6.7μM) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner. NU6027 attenuated G2/M arrest following DNA damage, inhibited RAD51 focus formation and increased the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy but not the antimitotic, paclitaxel. In A2780 cells sensitisation to cisplatin was greatest in cells with functional p53 and mismatch repair (MMR) and sensitisation to temozolomide was greatest in p53 mutant cells with functional MMR. Importantly, NU6027 was synthetically lethal when DNA single-strand break repair is impaired either through poly(ADP-ribose) polymerase (PARP) inhibition or defects in XRCC1. Conclusion: NU6027 inhibits ATR, impairing G2/M arrest and homologous recombination thus increasing sensitivity to DNA-damaging agents and PARP inhibitors. It provides proof of concept data for clinical development of ATR inhibitors.",
author = "A. Peasland and Wang, {L. Z.} and E. Rowling and S. Kyle and T. Chen and A. Hopkins and Cliby, {William Arthur} and Sarkaria, {Jann N} and G. Beale and Edmondson, {R. J.} and Curtin, {N. J.}",
year = "2011",
month = "7",
day = "26",
doi = "10.1038/bjc.2011.243",
language = "English (US)",
volume = "105",
pages = "372--381",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

AU - Peasland, A.

AU - Wang, L. Z.

AU - Rowling, E.

AU - Kyle, S.

AU - Chen, T.

AU - Hopkins, A.

AU - Cliby, William Arthur

AU - Sarkaria, Jann N

AU - Beale, G.

AU - Edmondson, R. J.

AU - Curtin, N. J.

PY - 2011/7/26

Y1 - 2011/7/26

N2 - Background: The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a key role in the signalling of stalled replication forks and DNA damage to cell cycle checkpoints and DNA repair. It has long been recognised as an important target for cancer therapy but inhibitors have proved elusive. As NU6027, originally developed as a CDK2 inhibitor, potentiated cisplatin in a CDK2-independent manner we postulated that it may inhibit ATR. Methods: Cellular ATR kinase activity was determined by CHK1 phosphorylation in human fibroblasts with inducible dominant-negative ATR-kinase dead expression and human breast cancer MCF7 cells. Cell cycle effects and chemo-and radiopotentiation by NU6027 were determined in MCF7 cells and the role of mismatch repair and p53 was determined in isogenically matched ovarian cancer A2780 cells.Results:NU6027 is a potent inhibitor of cellular ATR activity (IC50 6.7μM) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner. NU6027 attenuated G2/M arrest following DNA damage, inhibited RAD51 focus formation and increased the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy but not the antimitotic, paclitaxel. In A2780 cells sensitisation to cisplatin was greatest in cells with functional p53 and mismatch repair (MMR) and sensitisation to temozolomide was greatest in p53 mutant cells with functional MMR. Importantly, NU6027 was synthetically lethal when DNA single-strand break repair is impaired either through poly(ADP-ribose) polymerase (PARP) inhibition or defects in XRCC1. Conclusion: NU6027 inhibits ATR, impairing G2/M arrest and homologous recombination thus increasing sensitivity to DNA-damaging agents and PARP inhibitors. It provides proof of concept data for clinical development of ATR inhibitors.

AB - Background: The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a key role in the signalling of stalled replication forks and DNA damage to cell cycle checkpoints and DNA repair. It has long been recognised as an important target for cancer therapy but inhibitors have proved elusive. As NU6027, originally developed as a CDK2 inhibitor, potentiated cisplatin in a CDK2-independent manner we postulated that it may inhibit ATR. Methods: Cellular ATR kinase activity was determined by CHK1 phosphorylation in human fibroblasts with inducible dominant-negative ATR-kinase dead expression and human breast cancer MCF7 cells. Cell cycle effects and chemo-and radiopotentiation by NU6027 were determined in MCF7 cells and the role of mismatch repair and p53 was determined in isogenically matched ovarian cancer A2780 cells.Results:NU6027 is a potent inhibitor of cellular ATR activity (IC50 6.7μM) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner. NU6027 attenuated G2/M arrest following DNA damage, inhibited RAD51 focus formation and increased the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy but not the antimitotic, paclitaxel. In A2780 cells sensitisation to cisplatin was greatest in cells with functional p53 and mismatch repair (MMR) and sensitisation to temozolomide was greatest in p53 mutant cells with functional MMR. Importantly, NU6027 was synthetically lethal when DNA single-strand break repair is impaired either through poly(ADP-ribose) polymerase (PARP) inhibition or defects in XRCC1. Conclusion: NU6027 inhibits ATR, impairing G2/M arrest and homologous recombination thus increasing sensitivity to DNA-damaging agents and PARP inhibitors. It provides proof of concept data for clinical development of ATR inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=79960834396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960834396&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.243

DO - 10.1038/bjc.2011.243

M3 - Article

C2 - 21730979

AN - SCOPUS:79960834396

VL - 105

SP - 372

EP - 381

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -